CIBC Private Wealth Group LLC Grows Position in Zoetis Inc. $ZTS

CIBC Private Wealth Group LLC raised its stake in shares of Zoetis Inc. (NYSE:ZTS) by 81.4% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 1,681,306 shares of the company’s stock after purchasing an additional 754,452 shares during the period. CIBC Private Wealth Group LLC’s holdings in Zoetis were worth $246,009,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. Halbert Hargrove Global Advisors LLC lifted its position in shares of Zoetis by 496.6% during the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after buying an additional 144 shares in the last quarter. Financial Consulate Inc. purchased a new stake in Zoetis in the 3rd quarter worth approximately $39,000. SJS Investment Consulting Inc. increased its holdings in Zoetis by 1,606.3% in the 3rd quarter. SJS Investment Consulting Inc. now owns 273 shares of the company’s stock worth $40,000 after acquiring an additional 257 shares in the last quarter. TruNorth Capital Management LLC bought a new stake in Zoetis during the 3rd quarter worth approximately $42,000. Finally, Migdal Insurance & Financial Holdings Ltd. bought a new stake in Zoetis during the 3rd quarter worth approximately $46,000. Institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

Shares of Zoetis stock opened at $121.74 on Wednesday. The stock has a 50 day moving average of $124.96 and a 200 day moving average of $131.08. Zoetis Inc. has a 12 month low of $114.47 and a 12 month high of $172.23. The firm has a market cap of $51.39 billion, a PE ratio of 20.22, a PEG ratio of 1.80 and a beta of 0.95. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.08. The business had revenue of $2.39 billion during the quarter, compared to analysts’ expectations of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The firm’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter last year, the business posted $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, research analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be issued a $0.53 dividend. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.7%. Zoetis’s dividend payout ratio (DPR) is 35.22%.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Morgan Stanley set a $160.00 price target on shares of Zoetis in a research report on Thursday, December 18th. HSBC set a $140.00 price objective on shares of Zoetis in a research report on Wednesday, December 10th. The Goldman Sachs Group raised shares of Zoetis to a “buy” rating in a report on Monday, December 15th. Bank of America increased their price target on Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a research note on Friday, February 13th. Finally, Wall Street Zen raised Zoetis from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Six equities research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat, Zoetis presently has a consensus rating of “Hold” and a consensus target price of $152.91.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.